Efficacy and safety of semaglutide in non-alcoholic fatty liver disease.

Zhu K, Kakkar R, Chahal D, Yoshida EM, Hussaini T

World journal of gastroenterology1 Oct 2023Cited by 29 (Europe PMC)

PMID37899788PMCIDPMC10600803DOI10.3748/wjg.v29.i37.5327PepBankPUB-37899788

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

01HumanSystematic reviewEfficacy outcome
In patients with NAFLD, semaglutide increased the likelihood of NASH resolution in a meta-analysis of randomized trials.
In plain wordsIn pooled trials of people with fatty liver disease, semaglutide made resolution of NASH more likely.
Peptide
Semaglutide
Outcome
IncreaseNASH resolution
Study
n = 458
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Measurements
OR
3.18 ratio
NASH resolution
Source sentences
Summary
Semaglutide increased the likelihood of NASH resolution (OR: 3.18, 95%CI: 1.70, 5.95; P < 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
MEDLINE, CENTRAL, and EMBASE were searched from inception to May 1, 2023, to identify eligible randomized controlled trials (RCTs).
Report a problemFND-3789978801
02HumanSystematic reviewEfficacy outcome
In patients with NAFLD, semaglutide increased the likelihood of improvement in steatosis in a meta-analysis of randomized trials.
In plain wordsIn pooled trials of people with fatty liver disease, semaglutide made improvement in liver fat more likely.
Peptide
Semaglutide
Outcome
IncreaseSteatosis improvement (histology)
Study
n = 458
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Measurements
OR
2.83 ratio
steatosis improvement
Source sentences
Summary
improvement in steatosis (OR: 2.83, 95%CI: 1.19, 6.71; P = 0.03)
1 context sentence(design, population, supporting numbers)
Summary · context
MEDLINE, CENTRAL, and EMBASE were searched from inception to May 1, 2023, to identify eligible randomized controlled trials (RCTs).
Report a problemFND-3789978802
03HumanSystematic reviewEfficacy outcome
In patients with NAFLD, semaglutide increased the likelihood of improvement in lobular inflammation in a meta-analysis of randomized trials.
In plain wordsIn pooled trials of people with fatty liver disease, semaglutide made improvement in liver inflammation more likely.
Peptide
Semaglutide
Outcome
IncreaseLobular inflammation improvement
Study
n = 458
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Measurements
OR
1.81 ratio
lobular inflammation improvement
Source sentences
Summary
lobular inflammation (OR: 1.81, 95%CI: 1.11, 2.96; P = 0.02)
1 context sentence(design, population, supporting numbers)
Summary · context
MEDLINE, CENTRAL, and EMBASE were searched from inception to May 1, 2023, to identify eligible randomized controlled trials (RCTs).
Report a problemFND-3789978803
04HumanSystematic reviewEfficacy outcome
In patients with NAFLD, semaglutide increased the likelihood of improvement in hepatocellular ballooning in a meta-analysis of randomized trials.
In plain wordsIn pooled trials of people with fatty liver disease, semaglutide made improvement in liver cell ballooning more likely.
Peptide
Semaglutide
Outcome
IncreaseHepatocellular ballooning improvement
Study
n = 458
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Measurements
OR
2.92 ratio
hepatocellular ballooning improvement
Source sentences
Summary
hepatocellular ballooning (OR: 2.92, 95%CI: 1.83, 4.65; P < 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
MEDLINE, CENTRAL, and EMBASE were searched from inception to May 1, 2023, to identify eligible randomized controlled trials (RCTs).
Report a problemFND-3789978804
05HumanSystematic reviewEfficacy outcome
In patients with NAFLD, semaglutide did not improve fibrosis stage in a meta-analysis of randomized trials.
In plain wordsIn pooled trials of people with fatty liver disease, semaglutide did not improve liver fibrosis stage.
Peptide
Semaglutide
Outcome
No significant changeFibrosis stage
Study
n = 458
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Measurements
OR
0.71 ratio
fibrosis stage
Source sentences
Summary
but not fibrosis stage (OR: 0.71, 95%CI: 0.15, 3.41; P = 0.67)
1 context sentence(design, population, supporting numbers)
Summary · context
MEDLINE, CENTRAL, and EMBASE were searched from inception to May 1, 2023, to identify eligible randomized controlled trials (RCTs).
Report a problemFND-3789978805
06HumanSystematic reviewEfficacy outcome
In patients with NAFLD, semaglutide reduced alanine aminotransferase in a meta-analysis of randomized trials.
In plain wordsIn pooled trials of people with fatty liver disease, semaglutide lowered the liver enzyme ALT.
Peptide
Semaglutide
Outcome
DecreaseAlanine aminotransferase change
Study
n = 458
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Measurements
MD
−14.06 U/L
ALT
Source sentences
Summary
It also reduced alanine aminotransferase (MD: -14.06 U/L, 95%CI: -22.06, -6.07; P < 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
MEDLINE, CENTRAL, and EMBASE were searched from inception to May 1, 2023, to identify eligible randomized controlled trials (RCTs).
Report a problemFND-3789978808
07HumanSystematic reviewEfficacy outcome
In patients with NAFLD, semaglutide reduced aspartate aminotransferase in a meta-analysis of randomized trials.
In plain wordsIn pooled trials of people with fatty liver disease, semaglutide lowered the liver enzyme AST.
Peptide
Semaglutide
Outcome
DecreaseAspartate aminotransferase change
Study
n = 458
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Measurements
MD
−11.44 U/L
AST
Source sentences
Summary
aspartate aminotransferase (MD: -11.44 U/L, 95%CI: -17.23, -5.65; P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
MEDLINE, CENTRAL, and EMBASE were searched from inception to May 1, 2023, to identify eligible randomized controlled trials (RCTs).
Report a problemFND-3789978809
08HumanSystematic reviewEfficacy outcome
In patients with NAFLD, semaglutide decreased HbA1c in a meta-analysis of randomized trials.
In plain wordsIn pooled trials of people with fatty liver disease, semaglutide lowered HbA1c.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change
Study
n = 458
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
MD
−0.77%
HbA1c
Source sentences
Summary
decreased HgA1c (MD: -0.77%, 95%CI: -1.18, -0.37; P < 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
MEDLINE, CENTRAL, and EMBASE were searched from inception to May 1, 2023, to identify eligible randomized controlled trials (RCTs).
Report a problemFND-3789978810
09HumanSystematic reviewEfficacy outcome
In patients with NAFLD, semaglutide reduced body weight in a meta-analysis of randomized trials.
In plain wordsIn pooled trials of people with fatty liver disease, semaglutide led to weight loss.
Peptide
Semaglutide
Outcome
DecreaseWeight loss
Study
n = 458
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
MD
−6.53 kg
weight
Source sentences
Summary
weight loss (MD: -6.53 kg, 95%CI: -11.21, -1.85; P = 0.006)
1 context sentence(design, population, supporting numbers)
Summary · context
MEDLINE, CENTRAL, and EMBASE were searched from inception to May 1, 2023, to identify eligible randomized controlled trials (RCTs).
Report a problemFND-3789978811
10HumanSystematic reviewSafety outcome
In patients with NAFLD, semaglutide increased the occurrence of gastrointestinal side effects in a meta-analysis of randomized trials.
In plain wordsIn pooled trials of people with fatty liver disease, semaglutide caused more digestive side effects.
Peptide
Semaglutide
Outcome
IncreaseGastrointestinal side effects
Study
n = 458
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Measurements
OR
3.72 ratio
GI-related side effects
Source sentences
Summary
increased the occurrence of GI-related side effects (OR: 3.72, 95%CI: 1.68, 8.23; P = 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
MEDLINE, CENTRAL, and EMBASE were searched from inception to May 1, 2023, to identify eligible randomized controlled trials (RCTs).
Report a problemFND-3789978812
11HumanSystematic reviewSafety outcome
In patients with NAFLD, the overall risk of serious adverse events with semaglutide was similar to placebo in a meta-analysis.
In plain wordsIn pooled trials of people with fatty liver disease, serious adverse events were about as likely with semaglutide as with placebo.
Peptide
Semaglutide
Outcome
No significant changeSerious adverse events
Study
n = 458
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Measurements
OR
1.4 ratio
serious adverse events vs placebo
Source sentences
Summary
Overall risk of serious adverse events was similar compared to placebo (OR: 1.40, 95%CI: 0.75, 2.62; P < 0.29).
1 context sentence(design, population, supporting numbers)
Summary · context
MEDLINE, CENTRAL, and EMBASE were searched from inception to May 1, 2023, to identify eligible randomized controlled trials (RCTs).
Report a problemFND-3789978813
12HumanSystematic reviewEfficacy outcome
In patients with NAFLD, semaglutide reduced radiologically measured liver stiffness in a meta-analysis of randomized trials.
In plain wordsIn pooled trials of people with fatty liver disease, semaglutide reduced liver stiffness on imaging.
Peptide
Semaglutide
Outcome
DecreaseLiver stiffness (radiological)
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Measurements
SMD
−0.48 SD units
liver stiffness
Source sentences
Summary
Radiologically, semaglutide reduced liver stiffness (SMD: -0.48, 95%CI: -0.86, -0.11; P = 0.01)
1 context sentence(design, population, supporting numbers)
Summary · context
MEDLINE, CENTRAL, and EMBASE were searched from inception to May 1, 2023, to identify eligible randomized controlled trials (RCTs).
Report a problemFND-3789978806
13HumanSystematic reviewEfficacy outcome
In patients with NAFLD, semaglutide reduced radiologically measured steatosis in a meta-analysis of randomized trials, a borderline result (MD -4.96%, 95% CI -9.92 to 0.01; P = 0.05).
In plain wordsIn pooled trials of people with fatty liver disease, semaglutide reduced liver fat on imaging, but the result was borderline.
Peptide
Semaglutide
Outcome
DecreaseSteatosis (radiological)
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Measurements
MD
−4.96%
steatosis
Source sentences
Summary
and steatosis (MD: -4.96%, 95%CI: -9.92, 0.01; P = 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
MEDLINE, CENTRAL, and EMBASE were searched from inception to May 1, 2023, to identify eligible randomized controlled trials (RCTs).
Report a problemFND-3789978807

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.